- Home
- IVVD vs BUUU Comparison
IVVD vs BUUU Comparison
Compare IVVD & BUUU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- BUUU
- Stock Information
- Founded
- IVVD 2020
- BUUU 2017
- Country
- IVVD United States
- BUUU Hong Kong
- Employees
- IVVD N/A
- BUUU N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- BUUU Services-Misc. Amusement & Recreation
- Sector
- IVVD Health Care
- BUUU Consumer Discretionary
- Exchange
- IVVD Nasdaq
- BUUU Nasdaq
- Market Cap
- IVVD 63.4M
- BUUU 68.1M
- IPO Year
- IVVD 2021
- BUUU 2025
- Fundamental
- Price
- IVVD $1.60
- BUUU $8.22
- Analyst Decision
- IVVD Strong Buy
- BUUU
- Analyst Count
- IVVD 5
- BUUU 0
- Target Price
- IVVD $5.11
- BUUU N/A
- AVG Volume (30 Days)
- IVVD 4.4M
- BUUU 29.1K
- Earning Date
- IVVD 11-13-2025
- BUUU 01-01-0001
- Dividend Yield
- IVVD N/A
- BUUU N/A
- EPS Growth
- IVVD N/A
- BUUU N/A
- EPS
- IVVD N/A
- BUUU 0.04
- Revenue
- IVVD $46,210,000.00
- BUUU $5,754,120.00
- Revenue This Year
- IVVD $112.35
- BUUU N/A
- Revenue Next Year
- IVVD $272.14
- BUUU N/A
- P/E Ratio
- IVVD N/A
- BUUU $220.00
- Revenue Growth
- IVVD 1941.08
- BUUU 64.23
- 52 Week Low
- IVVD $0.35
- BUUU $3.67
- 52 Week High
- IVVD $2.74
- BUUU $9.50
- Technical
- Relative Strength Index (RSI)
- IVVD 71.86
- BUUU N/A
- Support Level
- IVVD $1.15
- BUUU N/A
- Resistance Level
- IVVD $1.15
- BUUU N/A
- Average True Range (ATR)
- IVVD 0.12
- BUUU 0.00
- MACD
- IVVD 0.02
- BUUU 0.00
- Stochastic Oscillator
- IVVD 99.85
- BUUU 0.00
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.